3.73
3.73 (0%)
As of Apr 17, 2025
Titan Pharmaceuticals Inc [TTNP]
Source:
Company Overview
Titan Pharmaceuticals, Inc is a pharmaceutical company that was previously developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura , for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate and a drug substance.
| Country | United States |
| Headquarters | san francisco, california |
| Phone Number | 6502444990 |
| Industry | manufacturing |
| CEO | David E. Lazar |
| Website | www.titanpharm.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-4.6 |
| Net Income | $-4.7 |
| Net Cash | $-3.9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -85.5% |
| Profit as % of Stockholder Equity | -192.9% |
Management Effectiveness
| Return on Equity | -192.9% |
| Return on Assets | -161% |
| Turnover Ratio | |
| EBITA | $-4.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $2.9 |
| Total Liabilities | $0.5 |
| Operating Cash Flow | $-3.9 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $-0.1 |
